Skip to main content

David J. Moliterno, MD

08/01/2008
ABSTRACT: Objectives. This study was designed to assess the feasibility and safety of enoxaparin in combination with glycoprotein (GP) IIb/IIIa inhibitors during percutaneous coronary intervention (PCI) as part of an early invasive strategy...
ABSTRACT: Objectives. This study was designed to assess the feasibility and safety of enoxaparin in combination with glycoprotein (GP) IIb/IIIa inhibitors during percutaneous coronary intervention (PCI) as part of an early invasive strategy...
ABSTRACT: Objectives. This study...
08/01/2008
Journal of Invasive Cardiology
06/19/2008
About TENACITY TENACITY (Tirofiban Novel Dosing vs. Abciximab with Evaluation of Clopidogrel and Inhibition of Thrombin Study) is a multi-center, double-blind, randomized comparison of tirofiban (Aggrastat®, Guilford Pharmaceuticals) and...
About TENACITY TENACITY (Tirofiban Novel Dosing vs. Abciximab with Evaluation of Clopidogrel and Inhibition of Thrombin Study) is a multi-center, double-blind, randomized comparison of tirofiban (Aggrastat®, Guilford Pharmaceuticals) and...
About TENACITY TENACITY...
06/19/2008
Cath Lab Digest
Commentary
06/26/2013
The observations from Dores et al are consistent with prior reports in that the rates of definite stent thrombosis are low and decreasing in recent years. The challenge remains how to afford to study such low frequency events with...
The observations from Dores et al are consistent with prior reports in that the rates of definite stent thrombosis are low and decreasing in recent years. The challenge remains how to afford to study such low frequency events with...
The observations from Dores et...
06/26/2013
Journal of Invasive Cardiology
Feature
06/19/2008
About TENACITY TENACITY (Tirofiban Novel Dosing vs. Abciximab with Evaluation of Clopidogrel and Inhibition of Thrombin Study) is a multi-center, double-blind, randomized comparison of tirofiban (Aggrastat®, Guilford Pharmaceuticals) and...
About TENACITY TENACITY (Tirofiban Novel Dosing vs. Abciximab with Evaluation of Clopidogrel and Inhibition of Thrombin Study) is a multi-center, double-blind, randomized comparison of tirofiban (Aggrastat®, Guilford Pharmaceuticals) and...
About TENACITY TENACITY...
06/19/2008
Cath Lab Digest
Feature
08/01/2008
Among patients with acute myocardial infarction (AMI), the efficacy of treatments that decrease mortality by coronary reperfusion and control of arrhythmia is dependent on time and access to acute medical care. Coronary reperfusion requires...
Among patients with acute myocardial infarction (AMI), the efficacy of treatments that decrease mortality by coronary reperfusion and control of arrhythmia is dependent on time and access to acute medical care. Coronary reperfusion requires...
Among patients with acute...
08/01/2008
Journal of Invasive Cardiology
Feature
08/01/2008
Continued from previous page Review of Primary PCI Since the introduction of PTCA more than 20 years ago, technical advances and increased operator experience have contributed to a steady improvement in the success rate of this procedure....
Continued from previous page Review of Primary PCI Since the introduction of PTCA more than 20 years ago, technical advances and increased operator experience have contributed to a steady improvement in the success rate of this procedure....
Continued from previous...
08/01/2008
Journal of Invasive Cardiology
Feature
08/01/2008
Platelets are now widely acknowledged as pivotal in the development of arterial thrombosis and its resultant acute ischemic coronary syndromes (ACS), including unstable angina (UA), non-Q wave myocardial infarction (NQWMI), ST-segment...
Platelets are now widely acknowledged as pivotal in the development of arterial thrombosis and its resultant acute ischemic coronary syndromes (ACS), including unstable angina (UA), non-Q wave myocardial infarction (NQWMI), ST-segment...
Platelets are now widely...
08/01/2008
Journal of Invasive Cardiology
Feature
08/01/2008
Continued from previous page PURSUIT. The PURSUIT trial was designed to evaluate eptifibatide as an adjunct to a broad spectrum of management strategies used to prevent death and MI in the 30 days following an urgent episode of UA or NQWMI....
Continued from previous page PURSUIT. The PURSUIT trial was designed to evaluate eptifibatide as an adjunct to a broad spectrum of management strategies used to prevent death and MI in the 30 days following an urgent episode of UA or NQWMI....
Continued from previous...
08/01/2008
Journal of Invasive Cardiology
Original Contribution
08/01/2008
Several randomized trials have demonstrated the efficacy of drug-eluting stents (DES) in reducing restenosis and the need for target vessel revascularization (TVR) in comparison to bare metal stents (BMS).1-3 Patient and lesion subsets...
Several randomized trials have demonstrated the efficacy of drug-eluting stents (DES) in reducing restenosis and the need for target vessel revascularization (TVR) in comparison to bare metal stents (BMS).1-3 Patient and lesion subsets...
Several randomized trials have...
08/01/2008
Journal of Invasive Cardiology
Clinical Editor's Corner
04/04/2021
As our old stock of Langstons is gone, I compiled a list of what I believe to be all the methods for aortic stenosis gradient assessment that involve only one arterial access and asked our expert colleagues about their alternative to the dual...
As our old stock of Langstons is gone, I compiled a list of what I believe to be all the methods for aortic stenosis gradient assessment that involve only one arterial access and asked our expert colleagues about their alternative to the dual...
As our old stock of Langstons is...
04/04/2021
Cath Lab Digest